9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report

Termination Date

11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

12. Lobbying

13. Organizations

INCOME relating to lobbying activities
for this reporting period was:

EXPENSE relating to lobbying activities
for this reporting period were:

Less than $5,000

Less than $5,000

$5,000 or more

$

30,000.00

$5,000 or more

$

Provide a good faith estimate, rounded to the nearest
$10,000,
of all lobbying related income from the client (including all
payments to the registrant by any other entity for lobbying
activities on behalf of the client).

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

15. General issue area code HCR

16. Specific lobbying issues

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 112th

S. 847, the Safe Chemicals Act of 2011The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

H.R. 2359, the Safe Cosmetics Act of 2011The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.

H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) andH.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.

H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.

House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.

Future Legislative Proposals:

The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.

The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.

The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

Regulation and Legislative Intent:

FDA AdvocacyIn addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.

Presidents Cancer Panel ReportThe Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel.

P.L. 110-314 - The Consumer Product Safety Commission Inprovement ActThe Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.

P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.